Indivior Pharmaceuticals Inc

indivior.com

What Do They Do?

Sells long-acting buprenorphine injections and sublingual medicines to healthcare providers and health systems treating opioid use disorder.

How Do They Make Money?

Wholesalers, specialty pharmacies and specialty distributors buy Indivior’s prescription medicines; each sale is counted when the customer receives the products.

FY2025 revenue

Who Are Their Customers?

Direct customers are often wholesalers, specialty pharmacies and specialty distributors; government programs and commercial insurers are often indirect customers. Indivior’s sales teams also work with healthcare providers, hospitals, addiction centers and criminal justice systems.

Do Revenues Turn Into Profits?

Yes. It kept 17 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$93M.

Operating income, FY2025

21% of revenue

▲ +589% vs FY2024 ($38M, 3%)

Net income, FY2025

17% of revenue

▲ +2900% vs FY2024 ($7M, 1%)

Free cash flow, FY2025

−8% of revenue

▼ Now a loss vs FY2024 ($7M, 1%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +14%; vs $302M in Q2 FY2025
Net income: ▲ +578%; vs $18M in Q2 FY2025

Aug 3, 2026 Agreed to merge with Supernus Under the agreement, Supernus would become Indivior’s wholly owned subsidiary and Indivior would be renamed Supernus, Inc.
Aug 3, 2026 Raised full-year financial guidance The updated outlook puts revenue at $1,295 million to $1,365 million and adjusted EBITDA at $700 million to $740 million.
Apr 30, 2026 Raised full-year financial guidance The revised outlook put revenue at $1,215 million to $1,285 million and adjusted EBITDA at $620 million to $660 million.

Who Do They Compete With?

Competes with Camurus and Braeburn

Comments